 Receptor, erbB-3
"Receptor, erbB-3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cell surface protein-tyrosine kinase receptor that is specific for NEUREGULINS. It has extensive homology to and can heterodimerize with the EGF Receptor (RECEPTOR, EPIDERMAL GROWTH FACTOR) and the erbB-2 receptor (RECEPTOR, ERBB-2). Overexpression of the erbB-3 receptor is associated with tumorigenesis.
| Descriptor ID |
D020893
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.175 D12.776.543.750.060.437 D12.776.543.750.750.400.360 D12.776.624.664.700.790 D23.101.840.721
|
| Concept/Terms |
Receptor, erbB-3- Receptor, erbB-3
- Receptor, erbB 3
- erbB-3 Receptor
- erbB-3 Protein
- erbB 3 Protein
- HER-3 Proto-Oncogene Protein
- HER 3 Proto Oncogene Protein
- Proto-Oncogene Protein, HER-3
- Proto-Oncogene Protein erbB-3
- Proto Oncogene Protein erbB 3
- erbB-3, Proto-Oncogene Protein
- Proto-Oncogene Proteins erbB-3
- Proto Oncogene Proteins erbB 3
- erbB-3, Proto-Oncogene Proteins
- c-erbB-3 Protein
- c erbB 3 Protein
- Proto-Oncogene Protein c-erbB-3
- Proto Oncogene Protein c erbB 3
- c-erbB-3, Proto-Oncogene Protein
|
Below are MeSH descriptors whose meaning is more general than "Receptor, erbB-3".
- Chemicals and Drugs [D]
- Enzymes and Coenzymes [D08]
- Enzymes [D08.811]
- Transferases [D08.811.913]
- Phosphotransferases [D08.811.913.696]
- Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
- Protein Kinases [D08.811.913.696.620.682]
- Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
- Receptor Protein-Tyrosine Kinases [D08.811.913.696.620.682.725.400]
- Receptor, erbB-3 [D08.811.913.696.620.682.725.400.175]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptor Protein-Tyrosine Kinases [D12.776.543.750.060]
- Receptor, erbB-3 [D12.776.543.750.060.437]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Growth Factor [D12.776.543.750.750.400]
- Receptor, erbB-3 [D12.776.543.750.750.400.360]
- Neoplasm Proteins [D12.776.624]
- Oncogene Proteins [D12.776.624.664]
- Proto-Oncogene Proteins [D12.776.624.664.700]
- Receptor, erbB-3 [D12.776.624.664.700.790]
- Biological Factors [D23]
- Biological Markers [D23.101]
- Tumor Markers, Biological [D23.101.840]
- Receptor, erbB-3 [D23.101.840.721]
Below are MeSH descriptors whose meaning is more specific than "Receptor, erbB-3".
This graph shows the total number of publications written about "Receptor, erbB-3" by people in this website by year, and whether "Receptor, erbB-3" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 1 | 0 | 1 | | 2012 | 1 | 0 | 1 | | 2014 | 1 | 0 | 1 | | 2015 | 0 | 1 | 1 | | 2016 | 1 | 2 | 3 | | 2017 | 0 | 2 | 2 | | 2021 | 1 | 1 | 2 | | 2022 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptor, erbB-3" by people in Profiles.
-
Hassani D, Jeddi-Tehrani M, Yousefi P, Mansouri-Fard S, Mobini M, Ahmadi-Zare H, Golsaz-Shirazi F, Amiri MM, Shokri F. Differential tumor inhibitory effects induced by HER3 extracellular subdomain-specific mouse monoclonal antibodies. Cancer Chemother Pharmacol. 2022 03; 89(3):347-361.
-
Wang Z, Goto Y, Allevato MM, Wu VH, Saddawi-Konefka R, Gilardi M, Alvarado D, Yung BS, O'Farrell A, Molinolo AA, Duvvuri U, Grandis JR, Califano JA, Cohen EEW, Gutkind JS. Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer. Nat Commun. 2021 04 22; 12(1):2383.
-
Hassani D, Amiri MM, Mohammadi M, Yousefi P, Judaki MA, Mobini M, Golsaz-Shirazi F, Jeddi-Tehrani M, Shokri F. A novel tumor inhibitory hybridoma monoclonal antibody with dual specificity for HER3 and HER2. Curr Res Transl Med. 2021 05; 69(2):103277.
-
Reynolds KL, Bedard PL, Lee SH, Lin CC, Tabernero J, Alsina M, Cohen E, Baselga J, Blumenschein G, Graham DM, Garrido-Laguna I, Juric D, Sharma S, Salgia R, Seroutou A, Tian X, Fernandez R, Morozov A, Sheng Q, Ramkumar T, Zubel A, Bang YJ. A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. BMC Cancer. 2017 Sep 12; 17(1):646.
-
Integrated genomic and molecular characterization of cervical cancer. Nature. 2017 03 16; 543(7645):378-384.
-
Iida M, Bahrar H, Brand TM, Pearson HE, Coan JP, Orbuch RA, Flanigan BG, Swick AD, Prabakaran PJ, Lantto J, Horak ID, Kragh M, Salgia R, Kimple RJ, Wheeler DL. Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab. Mol Cancer Ther. 2016 09; 15(9):2175-86.
-
Hamm CA, Moran D, Rao K, Trusk PB, Pry K, Sausen M, Jones S, Velculescu VE, Cristofanilli M, Bacus S. Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors. Mol Cancer Ther. 2016 07; 15(7):1746-56.
-
Choudhury NJ, Campanile A, Antic T, Yap KL, Fitzpatrick CA, Wade JL, Karrison T, Stadler WM, Nakamura Y, O'Donnell PH. Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations. J Clin Oncol. 2016 06 20; 34(18):2165-71.
-
Chapman KM, Medrano GA, Jaichander P, Chaudhary J, Waits AE, Nobrega MA, Hotaling JM, Ober C, Hamra FK. Targeted Germline Modifications in Rats Using CRISPR/Cas9 and Spermatogonial Stem Cells. Cell Rep. 2015 Mar 24; 10(11):1828-35.
-
Iida M, Brand TM, Starr MM, Huppert EJ, Luthar N, Bahrar H, Coan JP, Pearson HE, Salgia R, Wheeler DL. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy. Mol Cancer. 2014 Oct 24; 13:242.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|